Resomelagon shows reduced inflammation and joint damage in osteoarthritis model

Osteoarthritis (OA) is a highly prevalent joint disorder affecting 595 million people globally¹ characterized by chronic pain and functional impairment. Increasing evidence indicates that sustained low‑grade inflammation contributes to disease progression and structural joint damage.

“These data support a role for resomelagon in regulating early inflammatory processes in experimental osteoarthritis. Targeting pro‑resolving pathways via melanocortin receptor activation may represent a novel therapeutic strategy for modifying OA progression and associated pain,” said Mauro Teixeira, MD, PhD, Professor of Immunology, Universidade Federal de Minas Gerais (UFMG), Brazil.

The group led by Flávio Almeida Amaral, Department of Biochemistry and Immunology, Institute of Biological Sciences, Federal University of Minas Gerais, set up an experimental model of induced osteoarthritis in mice (destabilization of the medial meniscus, DMM) and evaluated effects on joint damage, pain, and inflammation. Preliminary findings indicate that resomelagon modulates early inflammatory responses following DMM surgery. Treatment was associated with altered mononuclear cell dynamics, regulation of melanocortin receptor expression, and reduced histopathological joint damage, suggesting an impact on disease progression.

“These preclinical findings support exploring OA as a potential new indication for resomelagon within our pro-resolution platform, and we look forward to following the continued research from our partners in Brazil,” said Thomas Jonassen, Chief Scientific Officer, SynAct Pharma.

Further data to be presented at the WCI2026 (17^th World Congress of Inflammation) to be held in Foz do Iguaçu, Brazil, September 8-12, 2026.

Reference: 1) Lancet Rheumatol 2023; 5: e508–22